Search - tctmd.com

Displaying 341 - 360 of 1458

Sort: Relevancy | Date

Presentation TVT 2021

Case examples and Clinical Outcomes with a Next-Generation Delivery System and Valve Design

Presenter: Lars Sondergaard

July 20, 2021

Presentation TVT 2021

Who Should You NOT Fracture: View From a Surgeon

Presenter: Mark Russo

July 20, 2021

Presentation TVT 2021

Surgical or TAVR Bioprosthetic Valve Failure: Preprocedural Planning, Best Practice Steps, and Complications

Presenter: Keith Allen

July 20, 2021

Presentation TVT 2021

Impact of THV Design to Achieve Supra-Annular Hemodynamics in an Intra-Annular Valve: Benchtop and Clinical Insights

Presenter: Gregory Fontana

July 20, 2021

Presentation TVT 2021

Remaining Unmet Technical and Clinical Needs in TAVR: Opportunities for Innovation to Improve Clinical Outcomes

Presenter: Azeem Latib

July 20, 2021

Presentation TVT 2021

Early neo2 Registry. Full Core-lab Results of TAVI With the New Acurate neo2 Valve

Presenter: Andreas Ruck

July 20, 2021

Presentation TVT 2021

The PARTNER 3 Bicuspid Registry for SAPIEN 3 Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk

Presenter: Mathew Williams

July 20, 2021

Presentation TVT 2021

Comparison of 1-Year Outcomes After Transcatheter Aortic Valve Replacement in Low-Risk Patients With Severe Bicuspid and Tricuspid Aortic Valve Stenosis

Presenter: John Forrest

July 20, 2021

Presentation TVT 2021

MASTER CLASS #1: Advanced Bioprosthetic Valve Failure Treated With TAVR

Presenter: John Webb

July 20, 2021

News Conference News TVT 2020

Stroke in TAVR: Full Impact of Embolic Devices, Anticoagulants, Technique Remain Unclear

Todd Neale

June 25, 2020

News Conference News TVT 2020

Device Explants After TAVR Rare but Risky

Michael O'Riordan

June 24, 2020

News Conference News TVT 2020

Real-world, Low-risk Patients Fare Well With Self-Expanding Evolut PRO

Shelley Wood

June 24, 2020

News Conference News TVT 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Michael O'Riordan

June 23, 2020

News Conference News TVT 2020

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

Michael O'Riordan

June 22, 2020

Presentation TVT 2020

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-risk Patients: A Propensity-Matched Analysis of 5-year Outcomes

Presenter: Susheel K. Kodali

June 21, 2020

Presentation TVT 2020

Outcomes of Surgical Explantation of TAVR– A Population-Based, Nationally-Representative Analysis

Presenter: Tsuyoshi Kaneko

June 21, 2020

Presentation TVT 2020

First Prospective Randomized Clinical Trial Assessing Incidence of Reduced Leaflet Motion and its Clinical Impact Following Transcatheter Aortic Valve Implantation

Presenter: Hasan Jilaihawi

June 21, 2020

Presentation TVT 2020

Valve-in-Surgical Valve with SAPIEN 3 for Transcatheter Aortic Valve Replacement:Propensity-Matched Analyses of Real World Data Based on the STS Predicted Risk of Mortality

Presenter: Tsuyoshi Kaneko

June 20, 2020

Presentation TVT 2020

Transcatheter Aortic Valve Replacement with Self-Expandable Supra Annular Valves for Failed Surgical Bioprostheses: Insights From the TVT Registry

Presenter: Guilherme F. Attizzani

June 20, 2020

Presentation TVT 2020

Transcatheter Aortic Valve Replacement using an Evolut PRO Bioprosthesis in Low Risk Patients with Aortic Stenosis

Presenter: Bruce Rutkin

June 20, 2020

Advertisement

Case examples and Clinical Outcomes with a Next-Generation Delivery System and Valve Design

Who Should You NOT Fracture: View From a Surgeon

Surgical or TAVR Bioprosthetic Valve Failure: Preprocedural Planning, Best Practice Steps, and Complications

Impact of THV Design to Achieve Supra-Annular Hemodynamics in an Intra-Annular Valve: Benchtop and Clinical Insights

Remaining Unmet Technical and Clinical Needs in TAVR: Opportunities for Innovation to Improve Clinical Outcomes

Early neo2 Registry. Full Core-lab Results of TAVI With the New Acurate neo2 Valve

The PARTNER 3 Bicuspid Registry for SAPIEN 3 Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk

Comparison of 1-Year Outcomes After Transcatheter Aortic Valve Replacement in Low-Risk Patients With Severe Bicuspid and Tricuspid Aortic Valve Stenosis

MASTER CLASS #1: Advanced Bioprosthetic Valve Failure Treated With TAVR

Stroke in TAVR: Full Impact of Embolic Devices, Anticoagulants, Technique Remain Unclear

Device Explants After TAVR Rare but Risky

Real-world, Low-risk Patients Fare Well With Self-Expanding Evolut PRO

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-risk Patients: A Propensity-Matched Analysis of 5-year Outcomes

Outcomes of Surgical Explantation of TAVR– A Population-Based, Nationally-Representative Analysis

First Prospective Randomized Clinical Trial Assessing Incidence of Reduced Leaflet Motion and its Clinical Impact Following Transcatheter Aortic Valve Implantation

Valve-in-Surgical Valve with SAPIEN 3 for Transcatheter Aortic Valve Replacement:Propensity-Matched Analyses of Real World Data Based on the STS Predicted Risk of Mortality

Transcatheter Aortic Valve Replacement with Self-Expandable Supra Annular Valves for Failed Surgical Bioprostheses: Insights From the TVT Registry

Transcatheter Aortic Valve Replacement using an Evolut PRO Bioprosthesis in Low Risk Patients with Aortic Stenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content